LKT Labs

Biochemicals for Life Science Research

Enalaprilat Dihydrate

Product ID E5200
Cas No. 84680-54-6
Purity ≥98%
Product Unit SizeCostQuantityStock
10 mg $163.90 In stock
50 mg $709.40 In stock
100 mg $1,308.90 In stock
Bulk Quote

Quicklinks

Description

Enalaprilat is the active metabolite of enalapril. Enalapril is an angiotensin-converting enzyme (ACE) inhibitor that is clinically used to treat hypertension, heart failure, and diabetic nephropathy. Enalapril exhibits antihypertensive activity. Enalapril prevents and reverses renovascular hypertension-induced smooth muscle hypertrophy, collagen deposition, carotid media thickness growth, and other parameters of arterial remodeling. Additionally, enalapril improves endothelial function in migraine sufferers by increasing levels of NO.

Product Info

Cas No.

84680-54-6
Purity

≥98%
Formula

C18H24N2O5 • 2H2O
Formula Wt.

384.42
Chemical Name

N-[(1S)-Carboxy- 3-phenylpropyl]-L-alanyl-L-proline dihydrate

IUPAC Name

(2S)-1-[(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]propanoyl]pyrrolidine-2-carboxylic acid;dihydrate

Synonym

Enalaprilic acid, Vasotec IV
Melting Point

148-151°C
Solubility

Slightly soluble in water (14 mg/mL at 60 oC) DMSO (64 mg/mL), methanol (14 mg/mL).

Appearance

White or almost white crystalline powder

Shipping and Storage

Store Temp

Ambient
Ship Temp

Ambient

Downloads

MSDS

E5200 MSDS PDF
Info Sheet

E5200 Info Sheet PDF

References

Chen JL, Shang QH, Hu W, et al. Role of TGF-β1/Smads pathway in carotid artery remodeling in renovascular hypertensive rats and prevention by Enalapril and Amlodipine. J Geriatr Cardiol. 2012 Jun;9(2):185-91. PMID: 22916067.

Bilan VP, Salah EM, Bastacky S, et al. Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats. J Endocrinol. 2011 Sep;210(3):293-308. PMID: 21680617.

Javanmard SH, Sonbolestan SA, Heshmat-Ghahdarijani K, et al. Enalapril improves endothelial function in patients with migraine: A randomized, double-blind, placebo-controlled trial. J Res Med Sci. 2011 Jan;16(1):26-32. PMID: 21448379.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • W9600

    WZ-4002

    EGFR (T790M) inhibitor.

    ≥98%
  • N0062

    D,L-Naproxen

    NSAID; COX-1/2 inhibitor.

    ≥98%
  • A6979

    Dihydroartemisinin

    Sesquiterpene lactone derived from Artemesia; m...

    ≥96%
  • B1603

    Beauvericin

    Cyclic hexadepsipeptide mycotoxin produced by C...

    ≥95%
  • A5302

    Anastrozole

    Aromatase inhibitor.

    ≥99%
  • T3196

    Thymoquinone

    Phytochemical from Nigella sativa.

    ≥98%
  • C4756

    Cloxacillin Sodium Monohydrate

    β-lactam; penicillin binding protein inhibitor...

    ≥98%
  • A686164

    Arecaidine Hydrochloride

    mAChR agonist, selective for M2.

    ≥98%
  • E6257

    Epothilone B

    Microtubule depolymerization inhibitor.

    ≥98%
  • E5210

    Endomorphin-1

    Endogenous opioid peptide; μOr agonist.

    ≥95%
  • G124086

    GDC-0152 Free Base

    Promotes degradation of cIAP1

    ≥96%
  • L8248

    Lumiracoxib

    NSAID; COX-2 inhibitor.

    ≥98%
  • M4004

    MK-2461

    MET, FGFR, PDGFR inhibitor.

    ≥99%
  • F4782

    Fludarabine Phosphate

    Nucleoside (adenosine) analog; DNA chain termin...

    ≥98%
  • R0272

    Rasagiline Mesylate

    MAO-A/B inhibitor.

    ≥98%
  • B0150

    Bambuterol Hydrochloride

    β2-adrenergic agonist, BChE inhibitor.

    ≥98%
  • A6934

    Aristolochic Acid C

    Found in Aristolochia and Radix; potential PLA2...

    ≥94%
  • R3476

    RITA

    p53 activator.

    ≥98%
  • T9969

    Tyrphostin AG490

    JAK2 inhibitor, potential EGFR inhibitor.

    ≥98%
  • L0250

    Laminin Peptide SIKVAV

    Laminin-derived hexapeptide.

    ≥98%